Margin of Insight
← Free primer

Investment Memorandum · Preview

For informational purposes only. Not investment advice.

Humana Inc.

HUM

UNDER REVIEW

May 27, 2026

Research Conclusion

HOLD/WATCH at $165. PWFV $171 (+4%). Fair Value ~$180 (+9%). BUY below $135; Strong Add below $115. The stock is priced at fair value with no margin of safety. Only at $135 does the risk/reward become acceptable. The critical binary catalyst is October 2026 CMS Stars preliminary ratings: recovery path changes thesis to $255+; stalled recovery triggers $70-100 bear case. October 2026 data is the verdict.

Company Overview & Moat Assessment

Humana Inc. (HUM) is the second-largest Medicare Advantage (MA) insurer in the US with ~5.4M individual MA members at FY2025 growing to ~6.3-6.8M following +25% AEP enrollment at FY2026. ~90%+ of revenue is Medicare-related (MA premiums, Part D pharmacy, Medicaid, dual-eligible). CenterWell is Humana's provider vertical: 300+ owned primary care clinics and 5,000+ PCP relationships managing outcomes for MA members (analogous to UNH/Optum but earlier-stage). FY2026 is an unprecedented trough: CMS Stars ratings collapse ($3.5B headwind) + V28 risk adjustment phase-in simultaneously compress EPS from $17.14 (FY2025A) to ≥$9.00 (FY2026E). Despite headwinds, +25% enrollment surge validates competitive positioning. The FY2026 trough is regulatory artifact, not structural deterioration—recovery path to $13-17 normalized EPS by FY2027-2028 is the thesis.

▲ Bull Case

  • ◆Stars rapid recovery 50%+ in 4+ plans by FY2027 + MLR normalization: Oct 2026 preliminary show HUM back to 50-55% in 4+ star; $2.5-3.0B Stars bonuses restore; MLR improves to 88.0-88.5%; CenterWell outcomes improve; Adj EPS $17; P/E 15x = $255 (+55%)
  • ◆Individual MA enrollment + CenterWell integration premium multiple: +25% cohort seasons into profitable members as MLR normalizes; CenterWell captures 40%+ members in owned clinics = structural MLR advantage; re-rate to UNH-like 18-20x multiple; Adj EPS $18-20; P/E 17x = $290-340 (+76-106%)
  • ◆CMS V28 fully absorbed + stable regulatory environment FY2027+: V28 phased complete by FY2026; risk model settles; premium adequacy restored; dual compression eliminated; Adj EPS $17-19; P/E 15-17x = $255-323

▼ Bear Case

  • ◆Stars stuck below 30% for FY2027 payment year: Oct 2026 preliminary show no meaningful improvement; structural benefit design or quality measurement issues; bonus gap widens vs. UNH/CVS; members generate negative margins at scale; Adj EPS $10; P/E 10x = $100 (-39%)
  • ◆CMS adverse FY2027 rate notice + Stars failure compound: Benchmark cuts reduce PMPM revenue from two directions; HUM exits unprofitable markets; enrollment reverses; Adj EPS $7; P/E 10x = $70 (-58%)
  • ◆MLR structural elevation—post-COVID utilization permanently higher: Deferred procedures + elevated chronic condition costs reset utilization baseline; MLR floor is structurally 90-91% not 87-88%; even with Stars recovery, normalized EPS $11-12 not $13-17; P/E 11x = $121-132 (-20-27%)
Primary Debate on Wall Street

“Primary debate: Is FY2026 temporary regulatory trough (Stars/V28) with earnings reverting to $13-17 by FY2027-2028, or is individual MA structurally impaired with persistently elevated MLR and inadequate premiums? Bull view: Stars collapse is known 2-3 year CMS measurement cycle. $3.5B headwind is quantified; V28 fully phased-in by end FY2026; 20+ years Stars management experience; +25% enrollment demonstrates HUM retains market competitiveness; CenterWell 300+ clinics create structural MLR advantage; normalized EPS $13-17+ by FY2027-2028. Bear view: Stars lagging indicator—quality issues take 3-4 years not 2-3 to reverse. Enrollment surge may be margin-dilutive if HUM priced benefits too aggressively (adverse selection). Individual MA structurally loss-making in FY2026-2027. MLR 90.5%+ is new normal not trough. Our view: Bull case requires observable Stars recovery (measured event not sustained competitive improvement). October 2026 preliminary data is verdict. At $165, market prices fair probability-weighted outcome with zero safety margin. Below $135, margin of safety makes risk/reward acceptable even if Stars recovery partial.”

Top Catalysts
  • ◆CMS Stars preliminary ratings October 2026 (binary: recovery >35% in 4+ star plans = bull $255+; stuck <30% = bear $70-100)
  • ◆CMS Stars final ratings January 2027 (confirms or reverses preliminary read)
  • ◆FY2027 EPS guidance February 2027 (first recovery thesis test; need ≥$12.50)
  • ◆Q2 2026 results July 2026 (MLR trajectory month-by-month; confirms trough depth control)
  • ◆CenterWell MLR data Q4 2026 / Feb 2027 (validates provider integration benefits flowing to P&L)
Top Risks
  • ◆Stars recovery stalls below 30% for FY2027 payment year (25% probability, high severity)
  • ◆CMS issues adverse FY2027 rate notice cutting MA benchmarks >2% (20% probability, high severity)
  • ◆Enrollment growth cohort at negative margins; MLR structurally >90% (30% probability, high severity)
  • ◆Post-COVID Medicare utilization permanently elevated; MLR floor 90-91% not 87-88% (25% probability, high severity)
  • ◆Dual compression: V28 residual drag + adverse rate notice compound (10% probability, severe tail risk)
  • ◆CenterWell clinic losses drag consolidated EPS during multi-year build-out (20% probability, moderate)

Full Memo Continues

5 more sections, locked

  • ●
    Valuation Range & DCF
    Base/bull/bear fair-value range, WACC, terminal growth, sensitivity to revenue + margin assumptions.
  • ●
    Risk/Reward Assessment
    Position-sizing framework with explicit upside/downside skew and entry conditions.
  • ●
    Management & Capital Allocation
    Multi-year capital-allocation track record, incentive alignment, and management readout.
  • ●
    Monitoring Framework
    What to watch each quarter — leading indicators and inflection signals tracked by the analyst.
  • ●
    Unresolved Questions
    Open analyst questions and follow-up research items — the depth signal.

For Agents — $2 per memo

Call the JSON API with a Stripe Shared Payment Token. No account, no signup — just pay and call.

GET /api/v1/research/HUM/memo
Authorization: Bearer spt_...

Fund managers — coverage subscriptions launching soon. See marginofinsight.com.

Margin of Insight

For informational purposes only. Not investment advice.